{"url_path":"/sec/dcoy/8-k/2026-07-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-304949-index.html","accession_number":"0001193125-26-304949","cik":"0001615219","ticker":"DCOY","issuer_name":"Decoy Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-304949-index.html","primary_entity_key":"0001615219","primary_entity_name":"Decoy Therapeutics Inc."},"word_count":355,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\n \n\nOn July 14, 2026, Decoy Therapeutics Inc. (the “Company”) convened its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of May 22, 2026, the record date for the Annual Meeting, there were 531,968 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 225,548, or 42.4%, were present in person or represented by proxy, which constituted a quorum.\n\nAt the Annual Meeting, the stockholders voted and: (1) re-elected or elected each of the Company’s three nominees for Class II director; (2) approved, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting; and (3) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nSet forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting.\n\nProposal 1. To elect three Class II directors to serve until the 2029 annual meeting or until their successors are duly elected and qualified:\n\n \n\n \n\nNominees\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\nPatricia Gauthier\n\n \n\n23,204\n\n \n\n4,110\n\n \n\n12\n\n \n\n198,222\n\nJonathan Lieber\n\n \n\n22,964\n\n \n\n4,349\n\n \n\n12\n\n \n\n198,223\n\nFrederick E. Pierce\n\n \n\n22,690\n\n \n\n4,624\n\n \n\n12\n\n \n\n198,222\n\n \n\n \n\nProposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting:\n\n \n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n21,278\n\n \n\n5,041\n\n \n\n1,007\n\n \n\n198,222\n\n \n\n \n\nProposal 3. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\n \n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n214,341\n\n \n\n9,584\n\n \n\n1,623\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nDecoy Therapeutics inc.\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: July 15, 2026\n\nBy:\n\n/s/ Mark J. Rosenblum\n\n \n\n \n\nMark J. Rosenblum\n\n \n\n \n\nExecutive Vice President and Chief Financial Officer"}